The importance of deubiquitinating enzymes in myeloma pathogenenesis, and their potential as drug targets, was recently demonstrated using an inhibitor targeting USP7 [15], and another targeting UCH-L5 and USP14, two proteasome-associated DUBs [14]. This evidence concerns the gene USP7 and plasma cell myeloma.